Skip to main content

Advertisement

SpringerLink
Log in

Malignant Cerebral Edema After Large Anterior Circulation Infarction: A Review

  • Cerebrovascular Disease and Stroke (D Greer, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Malignant infarction implies a large middle cerebral artery (MCA) stroke that leads to rapid clinical deterioration and edema formation, and can be associated with hemorrhagic transformation, herniation, and poor functional outcomes, including death. Malignant edema is brain edema formation that occurs in the setting of large territory infarction. This review discusses the most recent efforts in diagnosis, prevention, and management of malignant edema in acute ischemic strokes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996;53(4):309–15.

    Article  CAS  PubMed  Google Scholar 

  2. Moulin DE, Lo R, Chiang J, Barnett HJ. Prognosis in middle cerebral artery occlusion. Stroke. 1985;16(2):282–4.

    Article  CAS  PubMed  Google Scholar 

  3. Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following stroke: a prospective review. Stroke. 1984;15(3):492–6.

    Article  CAS  PubMed  Google Scholar 

  4. Kaste M, Waltimo O. Prognosis of patients with middle cerebral artery occlusion. Stroke. 1976;7(5):482–5.

    Article  CAS  PubMed  Google Scholar 

  5. Huttner HB, Schwab S. Malignant middle cerebral artery infarction: clinical characteristics, treatment strategies, and future perspectives. Lancet Neurol. 2009;8(10):949–58.

    Article  PubMed  Google Scholar 

  6. Jaramillo A, Góngora-Rivera F, Labreuche J, Hauw JJ, Amarenco P. Predictors for malignant middle cerebral artery infarctions: a postmortem analysis. Neurology. 2006;66(6):815–20.

    Article  CAS  PubMed  Google Scholar 

  7. Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicenter, open, randomized trial. Lancet Neurol. 2009;8(4):326–33.

    Article  PubMed  Google Scholar 

  8. Jüttler E, Schwab S, Schmiedek P, et al. Decompressive surgery for the treatment of malignant infarction of the middle cerebral artery (DESTINY): a randomized, controlled trial. Stroke. 2007;38(9):2518–25.

    Article  PubMed  Google Scholar 

  9. Vahedi K, Vicaut E, Mateo J, et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke. 2007;38(9):2506–17.

    Article  PubMed  Google Scholar 

  10. Frank JI. Large hemispheric infarction, deterioration, and intracranial pressure. Neurology. 1995;45(7):1286–90.

    Article  CAS  PubMed  Google Scholar 

  11. Donkin JJ, Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr Opin Neurol. 2010;23(3):293–9.

    Article  CAS  PubMed  Google Scholar 

  12. Walcott BP, Kahle KT, Simard JM. Novel treatment targets for cerebral edema. Neurotherapeutics. 2012;9(1):65–72. Outlines the pathophysiology of cerebral edema and discusses novel strategies for treating it.

    Article  PubMed  Google Scholar 

  13. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007;6(3):258–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Yan Y, Dempsey RJ, Flemmer A, Forbush B, Sun D. Inhibition of Na(+)-K(+)-Cl(-) cotransporter during focal cerebral ischemia decreases edema and neuronal damage. Brain Res. 2003;961(1):22–31.

    Article  CAS  PubMed  Google Scholar 

  15. Badaut J, Lasbennes F, Magistretti PJ, Regli L. Aquaporins in brain distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab. 2002;22(4):367–78.

    Article  CAS  PubMed  Google Scholar 

  16. Simard JM, Geng Z, Silver FL, et al. Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann N Y Acad Sci. 2012;1268:95–107.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Hofmeijer J, Algra A, Kappelle LJ, van der Worp HB. Predictors of life-threatening brain edema in middle cerebral artery infarction. Cerebrovasc Dis. 2008;25(1–2):176–84.

    Article  PubMed  Google Scholar 

  18. Walcott BP, Miller JC, Kwon CS, et al. Outcomes in severe middle cerebral artery ischemic stroke. Neurocrit Care. 2013.

  19. Toni D, Fiorelli M, Gentile M, et al. Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis. Arch Neurol. 1995;52(7):670–5.

    Article  CAS  PubMed  Google Scholar 

  20. Serena J, Blanco M, Castellanos M, et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke. 2005;36(9):1921–6.

    Article  CAS  PubMed  Google Scholar 

  21. Kernagis DN, Laskowitz DT. Evolving role of biomarkers in acute cerebrovascular disease. Ann Neurol. 2012;71(3):289–303. Provides an excellent review of the potential of biomarkers for the early detection of stroke.

    Article  CAS  PubMed  Google Scholar 

  22. Minnerup J, Wersching H, Ringelstein EB, et al. Prediction of malignant middle cerebral artery infarction using computed tomography-based intracranial volume reserve measurements. Stroke. 2011;42(12):3403–9.

    Article  PubMed  Google Scholar 

  23. Bektas H, Wu TC, Kasam M, et al. Increased blood-brain barrier permeability on perfusion CT might predict malignant middle cerebral artery infarction. Stroke. 2010;41(11):2539–44.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Hom J, Dankbaar JW, Soares BP, et al. Blood-brain barrier permeability assessed by perfusion CT predicts symptomatic hemorrhagic transformation and malignant edema in acute ischemic stroke. Am J Neuroradiol. 2011;32(1):41–8.

    CAS  PubMed  Google Scholar 

  25. Thomalla G, Cheng B, Ebinger M, et al. DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4 · 5 hours of symptom onset (PRE-FLAIR): a multicenter observational study. Lancet Neurol. 2011;10(11):978–86.

    Article  PubMed  Google Scholar 

  26. Mangla R, Ekhom S, Jahromi BS, Almast J, Mangla M, Westesson PL. CT perfusion in acute stroke: know the mimics, potential pitfalls, artifacts, and technical errors. Emerg Radiol. 2013.

  27. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59(3):467–77.

    Article  PubMed  Google Scholar 

  28. Young AR, Ali C, Duretête A, Vivien D. Neuroprotection and stroke: time for a compromise. J Neurochem. 2007;103(4):1302–9.

    Article  CAS  PubMed  Google Scholar 

  29. Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis. 2011;20(1):47–54.

    Article  PubMed  Google Scholar 

  30. Switzer JA, Hess DC, Ergul A, et al. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke. 2011;42(9):2633–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Fagan SC, Waller JL, Nichols FT, et al. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke. 2010;41(10):2283–7.

    Article  CAS  PubMed  Google Scholar 

  32. Kono S, Deguchi K, Morimoto N, et al. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. J Stroke Cerebrovasc Dis. 2013.

  33. Feng S, Yang Q, Liu M, et al. Edaravone for acute ischaemic stroke. Cochrane Database Syst Rev. 2011;12, CD007230.

    PubMed  Google Scholar 

  34. Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007;38(9):2526–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Kunte H, Busch MA, Trostdorf K, et al. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol. 2012;72(5):799–806.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Li H, Wang D. Mild hypothermia improves ischemic brain function via attenuating neuronal apoptosis. Brain Res. 2011;1368:59–64.

    Article  CAS  PubMed  Google Scholar 

  37. Wu TC, Grotta JC. Hypothermia for acute ischaemic stroke. Lancet Neurol. 2013;12(3):275–84.

    Article  PubMed  Google Scholar 

  38. Hemmen TM, Raman R, Guluma KZ, et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke. 2010;41(10):2265–70.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Horn CM, Sun CH, Nogueira RG, et al. Endovascular Reperfusion and Cooling in Cerebral Acute Ischemia (ReCCLAIM I). J Neurointerv Surg. 2013.

  40. Sandercock PA, Soane T. Corticosteroids for acute ischaemic stroke. Cochrane Database Syst Rev. 2011;9, CD000064.

    PubMed  Google Scholar 

  41. Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49(4):391–402. 402.e391–2.

    Article  PubMed  Google Scholar 

  42. Stein DG. Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev. 2008;57(2):386–97.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Zador Z, Stiver S, Wang V, Manley GT. Role of aquaporin-4 in cerebral edema and stroke. Handb Exp Pharmacol. 2009;190:159–70.

    Article  CAS  PubMed  Google Scholar 

  44. Martins AP, Marrone A, Ciancetta A, et al. Targeting aquaporin function: potent inhibition of aquaglyceroporin-3 by a gold-based compound. PLoS One. 2012;7(5):e37435.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Chu H, Tang Y, Dong Q. Protection of vascular endothelial growth factor to brain edema following intracerebral hemorrhage and its involved mechanisms: effect of Aquaporin-4. PLoS One. 2013;8(6):e66051.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. O'Donnell ME, Tran L, Lam TI, Liu XB, Anderson SE. Bumetanide inhibition of the blood-brain barrier Na-K-Cl cotransporter reduces edema formation in the rat middle cerebral artery occlusion model of stroke. J Cereb Blood Flow Metab. 2004;24(9):1046–56.

    Article  PubMed  Google Scholar 

  47. Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.

    Article  PubMed  Google Scholar 

  48. Chesnut RM, Temkin N, Carney N, et al. A trial of intracranial-pressure monitoring in traumatic brain injury. N Engl J Med. 2012;367(26):2471–81.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Donato T, Shapira Y, Artru A, Powers K. Effect of mannitol on cerebrospinal fluid dynamics and brain tissue edema. Anesth Analg. 1994;78(1):58–66.

    Article  CAS  PubMed  Google Scholar 

  50. Bereczki D, Fekete I, Prado GF, Liu M. Mannitol for acute stroke. Cochrane Database Syst Rev. 2007;3, CD001153.

    PubMed  Google Scholar 

  51. Lazaridis C, Neyens R, Bodle J, DeSantis SM. High-osmolarity saline in neurocritical care: systematic review and meta-analysis. Crit Care Med. 2013;41(5):1353–60.

    Article  PubMed  Google Scholar 

  52. Kamel H, Navi BB, Nakagawa K, Hemphill JC, Ko NU. Hypertonic saline vs mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. Crit Care Med. 2011;39(3):554–9.

    Article  CAS  PubMed  Google Scholar 

  53. Diringer MN, Scalfani MT, Zazulia AR, Videen TO, Dhar R. Cerebral hemodynamic and metabolic effects of equi-osmolar doses mannitol and 23.4 % saline in patients with edema following large ischemic stroke. Neurocrit Care. 2011;14(1):11–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Walcott BP, Kuklina EV, Nahed BV, et al. Craniectomy for malignant cerebral infarction: prevalence and outcomes in US hospitals. PLoS One. 2011;6(12):e29193. Provides large-scale epidemiologic data of the incidence in craniectomy surgeries in the past decade. It shows an increase in decompressive surgeries after the publication of the three randomized controlled trials that came out in favor of surgery in 2007-2009.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  55. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007;6(3):215–22.

    Article  PubMed  Google Scholar 

  56. McKenna A, Wilson CF, Caldwell SB, Curran D. Functional outcomes of decompressive hemicraniectomy following malignant middle cerebral artery infarctions: a systematic review. Br J Neurosurg. 2012;26(3):310–5. The first systematic review that examines functional outcome following decompressive surgery in patients with malignant cerebral edema.

    Article  PubMed  Google Scholar 

  57. Zhao J, Su YY, Zhang Y, et al. Decompressive hemicraniectomy in malignant middle cerebral artery infarct: a randomized controlled trial enrolling patients up to 80 years old. Neurocrit Care. 2012;17(2):161–71.

    Article  PubMed  Google Scholar 

  58. Jüttler E, Bösel J, Amiri H, et al. DESTINY II: DEcompressive surgery for the treatment of malignant INfarction of the middle cerebral arterY II. Int J Stroke. 2011;6(1):79–86.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Allison E. Arch declares that she has no conflicts of interest. Dr. Kevin N. Sheth reported received grants from Remedy Pharmaceuticals and NIH.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Neurocritical Care and Emergency Neurology, Yale University School of Medicine, 15 York Street, LCI Suite 710, New Haven, CT, 06510, USA

    Allison E. Arch MD, MPH & Kevin N. Sheth MD, FAHA

Authors
  1. Allison E. Arch MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin N. Sheth MD, FAHA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allison E. Arch MD, MPH.

Additional information

This article is part of the Topical Collection on Cerebrovascular Disease and Stroke

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arch, A.E., Sheth, K.N. Malignant Cerebral Edema After Large Anterior Circulation Infarction: A Review. Curr Treat Options Cardio Med 16, 275 (2014). https://doi.org/10.1007/s11936-013-0275-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-013-0275-0

Keywords

Search

Navigation